Sequencing of antiretroviral therapy in children in low-and middle-income countries

Current Opinion in HIV and AIDS

Volumn 5, Issue 1, 2010, Pages 54-60

  Sohn, Annette H ^a   Nuttall, James J C ^b   Zhang, Fuije ^c  

^a Foundation for AIDS Research   (Thailand)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Antiretroviral therapy; Pediatric HIV; Regimen sequencing; Resistance; Treatment failure

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

AFRICA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ASIA; BONE DENSITY; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG CLEARANCE; DRUG COST; DRUG DOSE SEQUENCE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENOTYPE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STRAIN IDENTIFICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS MUTATION; VIRUS STRAIN;

ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; INFANT; POVERTY; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 74349104237     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283339bd8     Document Type: Review

References (58)

1. WHO. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access, recommendations for a public-health approach; 2006.
2. WHO. Report of the WHO Technical Reference Group, Paediatric HIV/ART Care Guideline Group Meeting. Geneva, Switzerland: WHO; 10-11 April 2008; 2008.
3. UNICEF. Children and AIDS: Third Stocktaking Report, 2008. Geneva: UNICEF; 2009.
4. Lindsey JC, Malee KM, Brouwers P, Hughes MD. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics 2007; 119:e681-e693.
5. Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis 2008; 46:507-515. (Pubitemid 351263487)
6. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997; 336:1337-1342.
7. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244.
8. Jaspan HB, Berrisford AE, Boulle AM. Two-year outcomes of children on nonnucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J 2008; 27:993-998.
9. Van Zyl GU, Van Der Merwe L, Claassen M, et al. Protease inhibitor resistance in South African children with virologic failure. Pediatr Infect Dis J 2009 Sep 24. [Epub ahead of print]
10. Chakraborty R, Smith CJ, Dunn D, et al. HIV-1 drug resistance in HIV-1- infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J 2008; 27:457-459.
11. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46:187-193.
12. Prasitsuebsai W, Bowen A, Pang J, et al. Regional survey of HIV clinical care resources and management practices in the TREAT Asia Pediatric Program. Australasian Society of Infectious Diseases, Annual Scientific Conference, Sydney; 25-28 March 2009; 2009.
13. Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, et al. HIV-1 drug resistance mutations in children who failed nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Southeast Asian J Trop Med Public Health 2009; 40:83-88.
14. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V. Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J 2009; 28:826-830.
15. Sunpath H, Zanoni B, Marconi V, et al. Longitudinal analysis of a pediatric cohort who failed first-line HAART in an ARV roll-out site in KwaZulu-Natala, South Africa [abstract #888]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec, Canada; 2009.
16. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49:454-462.
17. Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-1977.
18. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
19. Davies MA, Wood R, Van Cutsem G, et al. Virologic failure and second-line antiretroviral therapy (ART) in children in South Africa: the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa collaboration [abstract #MOAB104]. 5th Conference on HIV Pathogenesis, Treatment and Prevention, 26-29 July 2009; Cape Town, South Africa; 2009.
20. Bock P, Boulle A, White C, et al. Provision of antiretroviral therapy to children within the public sector of South Africa. Trans R Soc Trop Med Hyg 2008; 102:905-911.
21. Working Group on Antiretroviral Therapy and Medical Management of HIVInfected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection; 2009.
22. Sohn AH, Ananworanich J. Highly active antiretroviral therapy for children with treatment failure. HIV Ther 2009; 28:826-830.
23. WHO. WHO list of prequalified medicinal products. http://www.who.int/ prequal/query/ProductRegistry.aspx?list=ha. [Accessed 23 February 2009]
24. Pillay V, Pillay C, Kantor R, et al. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24:1449-1454.
25. Achan J, Pasutti W, Gati B, et al. Drug resistance with virologic failure in HIV+ Ugandan children on ART: consequences for second-line therapy [abstract #889]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec, Canada; 2009.
26. Cross SJ, Rodman JH, Lindsey JC, et al. Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents. J Acquir Immune Defic Syndr 2009; 51:54-59.
27. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002; 359:733-740.
28. Zhao W, Farrelly L, Compagnucci A, et al. PENTA 15: once-daily abacavir and lamivudine as part of combination antiretroviral therapy to 48 weeks in HIV-1 infected children aged 3 to 36 months [abstract #O-04]. 1st International Workshop on HIV Pediatrics; 17-18 July 2009; Cape Town, South Africa; 2009.
29. Zhang F, Haberer JE, Zhao Y, et al. Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes. J Acquir Immune Defic Syndr 2007; 46:594-598.
30. Zhang F, Haberer J, Wei H, et al. Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: implications for paediatric treatment in the developing world. Int J STD AIDS 2009; 20:406-409.
31. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J 2009; 28:619-625.
32. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:e711-e718.
33. Vigano A, Zuccotti G, Giacomet V, et al. Long-term effect of HAART containing tenofovir on bone mass in HIV-infected children and adolescents: a 48- month longitudinal assessment [abstract #913]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec, Canada; 2009.
34. Vigano A, Zuccotti GV, Martelli L, et al. Renal safety of tenofovir in HIVinfected children: a prospective, 96-week longitudinal study. Clin Drug Investig 2007; 27:573-581.
35. Turner D, Brenner B, Routy JP, et al. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37:1627-1631. (Pubitemid 39658205)
36. Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80:4971-4977.
37. Hosseinipour MC, Van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
38. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector - progress report 2008. Geneva, Switzerland: WHO; 2008.
39. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J 2007; 26:953-956.
40. Lapphra K, Vanprapar N, Chearskul S, et al. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. Int J Infect Dis 2008; 12:e33-e38.
41. Larru B, Resino S, Bellon JM, et al. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pretreated vertically HIV-infected children. J Antimicrob Chemother 2008; 61:183-190.
42. Rutstein RM, Samson P, Aldrovandi G, et al. Effect of atazanavir on serum cholesterol and triglyceride levels in HIV-infected infants, children, and adolescents: PACTG 1020A [abstract #774]. 12th Conference on Retroviruses and Opportunistic Infections; 22-25 February 2005; Boston, Massachusetts, United States; 2005.
43. Mallolas J, Podzamczer D, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr 2009; 51:29-36.
44. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
45. 17th Expert Committee on the Selection and Use of Essential Medicines. Application for listing of atazanavir for the treatment of HIV-1 infection on the WHO model list of essential medicines. Geneva, Switzerland: WHO; 2009.
46. Kosalaraksa P, Bunupuradah T, Engchanil C, et al. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J 2008; 27:623-628.
47. Bunupuradah T, Lumbiganon P, Puthanakit T, et al. Simplifying antiretroviral treatment in virally-suppressed children by switching from double boosted protease inhibitor to lopinavir/ritonavir monotherapy [abstract #MOPEB062]. 5th Conference on HIV Pathogenesis, Treatment and Prevention; 26-29 July 2009; Cape Town, South Africa; 2009.
48. Guidelines for the management of HIV-infected children. National Department of Health South Africa; 2005. http://www.doh.gov.za/docs/facts-f. html. [Accessed 6 July 2009]
49. Muller AD, Myer L, Jaspan H. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy. Clin Infect Dis 2009; 48:e3-e5.
50. Coovadia A, Abrams E, Strehlau R, et al. Randomized clinical trial of switching to nevirapine-based therapy for infected children exposed to nevirapine prophylaxis [abstract #MOAB103]. 5th Conference on HIV Pathogenesis, Treatment and Prevention; 26-29 July 2009; Cape Town, South Africa; 2009.
51. Kline MW, Rugina S, Ilie M, et al. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir- containing highly active antiretroviral therapy. Pediatrics 2007; 119:e1116-e1120.
52. Ramos JT, De Jose MI, Duenas J, et al. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1- infected children experienced with three classes of antiretrovirals. Pediatr Infect Dis J 2005; 24:867-873.
53. Bologna R, Rugina S, Cahn P, et al. Safety and efficacy of darunavir coadministered with low-dose ritonavir in treatment-experienced children and adolescents at Week 24 [abstract #75LB]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts, USA; 2008.
54. Salazar JC, Cahn P, Yogev R, et al. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS 2008; 22:1789-1798.
55. Wiznia A, Samson P, Acosta E, et al. Safety and efficacy of raltegravir in pediatric HIV infection: preliminary analysis from the international maternal pediatric adolescent AIDS clinical trial group, P1066 [abstract #874]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec, Canada; 2009.
56. Thuret I, Tamalet C, Reliquet V, et al. Raltegravir in children and adolescents: the French Expanded Access Program [abstract #873]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec, Canada; 2009.
57. Vigano A, Meroni L, Marchetti G, et al. Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1. Antivir Ther 2008; 13: 839-843.
58. Kekitinwa A, Friedman D, Coakley E, Lie Y, Graziano F. Profiling etravirine resistance in Ugandan children with extended failure of a NNRTI-inclusive regimen as first line ART [abstract #891]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec, Canada; 2009.